Upcoming events – Novartis’s asthma Zeal and Alnylam's lumasiran test
Novartis hopes to buck the trend with its DP2 inhibitor fevipiprant, while Alnylam looks for enlightenment with lumasiran.
Venture cash gets even more concentrated
The latest venture capital numbers suggest that 2019 will see a healthy amount raised, but the falling number of rounds could be a worry.
Esmo 2019 – PD-L1 status moves centre stage in bladder cancer
Roche’s Imvigor-130 study supports Tecentriq’s continued use in urothelial bladder cancer – up to a point.
Upcoming events – Aurinia and Principia face autoimmune tests
Aurinia hopes to light up with Aurora data, while Principia's BTK inhibitor PRN1008 is put to the test.
Upcoming events – Obseva's first fibroid foray and Newron's test in Retts
Obseva awaits data that could make linzagolix third to market, while Newron looks for a starring role in Retts.
Ardelyx Amplified by first hyperphosphataemia success
A win with a tenapanor combo could bode well for the project’s monotherapy chances.
Incontinence failure puts Viveve under stress
With little cash in the bank and creditors soon to start pressing, a trial failure is a disaster for Viveve.
Positive data Kalm Cara investors
Cara Therapeutics’ stock shot up 18% today on data derisking two key projects.
Reata’s big test approaches
Hopes are high as a phase III readout approaches for Reata Pharmaceuticals’ lead project, bardoxolone.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.